Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York state

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 5, 2006, Pages 614-619

  Karchava, Marine ^a   Pulver, Wendy ^b   Smith, Lou ^b   Philpott, Sean ^a   Sullivan, Timothy J ^a   Wethers, Judith ^a   Parker, Monica M ^a  

^a WADSWORTH CENTER   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

HIV drug resistance; Perinatal; Prevalence; Subtype diversity

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; PERINATAL PERIOD; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTI-HIV AGENTS; CLUSTER ANALYSIS; DISEASE TRANSMISSION, VERTICAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENOME, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MUTATION; NEW YORK; PHYLOGENY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; STATISTICS;

EID: 33746779456     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000225871.87456.e7     Document Type: Article

References (32)

1. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. February 25, 2005. Available at: http://aidsinfo.nih.gov/guidelines/perinatal/PER_022405.pdf.
2. Mofenson LM. Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 serosurvey of childbearing women. Arch Pediatr Adolesc Med. 2004;158:422-425.
3. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-1401.
4. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
6. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-2180.
7. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
8. Yerly S,Kaiser L,Race E, et al.Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet. 1999;354:729-733.
9. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181-188.
10. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS. 2002;16:1511-1519.
11. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr. 2003;32:292-297.
12. Charbonneau TT, Wade NA, Weiner L, et al. Vertical transmission of HIV in New York State: a basis for statewide testing of newborns. AIDS Patient Care STDS. 1997;11:227-236.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13:51-57.
14. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.
15. Kumar S, Tamura K, Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform. 2004;5:150-163.
16. Kemp SD, Shi C, Bloor S, et al. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol. 1998;72:5093-5098.
17. Quiros-Roldan E, Airoldi M, Moretti F, et al. Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. J Clin Lab Anal. 2002;16:76-78.
18. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857-2867.
19. Newstein M, Losikoff P, Caliendo A, et al. Prevalence and persistence of nonnucleoside reverse transcriptase inhibitor mutations in the female genital tract. J Acquir Immune Defic Syndr. 2005;38:364-366.
20. Juethner SN, Williamson C, Ristig MB, et al. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr. 2003;32:153-156.
21. Van Tine BA, Shaw GM, Aldrovandi G. Mother-to-infant transmission of the human immunodeficiency virus during primary infection. N Engl J Med. 1999;341:1548.
22. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002;76:1753-1761.
23. Briones C, Perez-Olmeda M, Rodriguez C, et al. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr. 2001;26:145-150.
24. Gandhi RT, Wurcel A, Rosenberg ES, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis. 2003;37:1693-1698.
25. Little SJ, Dawson K, Hellmann NS, et al. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. Antivir Ther. 2003:8.
26. Smith MS, Koerber KL, Pagano JS. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. J Infect Dis. 1994;169:184-188.
27. Weidle PJ, Ganea CE, Irwin KL, et al. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis. 2000;181:470-475.
28. Brodine SK, Starkey MJ, Shaffer RA, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003;17:2521-2527.
29. Delwart EL, Orton S, Parekh B, et al. Two percent of HIV-positive US blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses. 2003;19:1065-1070.
30. Kline NE, Schwarzwald H, Kline MW. False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection. Pediatr Infect Dis J. 2002;21:885-886.
31. Obaro SK, Losikoff P, Harwell J, et al. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. Pediatr Infect Dis J. 2005;24:183-184.
32. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. November 3, 2005. Available at: http://aidsinfo.nih. gov/guidelines/pediatric/PED_11032005.pdf.